1.18
1.18 (0%)
As of Feb 14, 2025
Coherus Biosciences, Inc. [CHRS]
Source:
Company Overview
Coherus Biosciences, Inc. is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer.
| Country | United States |
| Headquarters | redwood city, california |
| Phone Number | ( 650 ) 649-3530 |
| Industry | manufacturing |
| CEO | Dennis M. Lanfear |
| Website | www.coherus.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $267 |
| Operating Profit | $-111.7 |
| Net Income | $28.5 |
| Net Cash | $0 |
Profit Ratios
| Gross Margin | $149.4 |
| Operating Margin | -41.8 |
| Profit as % of Revenues | 524.1% |
| Profit as % of Assets | 5.3% |
| Profit as % of Stockholder Equity | -21.6% |
Management Effectiveness
| Return on Equity | -21.6% |
| Return on Assets | 6.4% |
| Turnover Ratio | 49.5% |
| EBITA | $-111.7 |
Balance Sheet and Cash Flow Measures
| Total Assets | $448.5 |
| Total Liabilities | $580.5 |
| Operating Cash Flow | $0 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $0 |
